vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Logistic Properties of the Americas (LPA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $50.1M, roughly 1.7× Logistic Properties of the Americas). Logistic Properties of the Americas produced more free cash flow last quarter ($21.4M vs $-61.9M).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Logistic Properties of the Americas is a specialized industrial real estate firm that acquires, develops and manages logistics properties across North, Central and South America. Its portfolio includes distribution centers, warehouses and last-mile delivery facilities, serving e-commerce, retail, manufacturing and third-party logistics clients.
IOVA vs LPA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $50.1M |
| Net Profit | — | $16.1M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 81.7% |
| Net Margin | — | 32.1% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $50.1M | ||
| Q3 25 | $67.5M | $32.7M | ||
| Q2 25 | $60.0M | $21.5M | ||
| Q1 25 | $49.3M | $10.5M | ||
| Q4 24 | $73.7M | — | ||
| Q3 24 | $58.6M | $19.2M | ||
| Q2 24 | $31.1M | — | ||
| Q1 24 | $715.0K | $9.2M |
| Q4 25 | — | $16.1M | ||
| Q3 25 | $-91.3M | — | ||
| Q2 25 | $-111.7M | — | ||
| Q1 25 | $-116.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | — | ||
| Q2 24 | $-97.1M | — | ||
| Q1 24 | $-113.0M | — |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 81.7% | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | -189.8% | — | ||
| Q1 25 | -245.8% | — | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | -152.1% | — | ||
| Q2 24 | -327.6% | — | ||
| Q1 24 | -16464.6% | — |
| Q4 25 | — | 32.1% | ||
| Q3 25 | -135.3% | — | ||
| Q2 25 | -186.2% | — | ||
| Q1 25 | -235.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | — | ||
| Q2 24 | -312.2% | — | ||
| Q1 24 | -15800.8% | — |
| Q4 25 | — | $0.33 | ||
| Q3 25 | — | $0.09 | ||
| Q2 25 | $-0.33 | $-0.06 | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | $-1.26 | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $27.3M |
| Total DebtLower is stronger | — | $296.8M |
| Stockholders' EquityBook value | $698.6M | $324.6M |
| Total Assets | $913.2M | $700.8M |
| Debt / EquityLower = less leverage | — | 0.91× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $27.3M | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | — | ||
| Q3 24 | $397.5M | — | ||
| Q2 24 | $412.5M | — | ||
| Q1 24 | $356.2M | $1.1M |
| Q4 25 | — | $296.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | $324.6M | ||
| Q3 25 | $702.3M | — | ||
| Q2 25 | $698.5M | — | ||
| Q1 25 | $767.9M | — | ||
| Q4 24 | $710.4M | — | ||
| Q3 24 | $773.5M | — | ||
| Q2 24 | $768.5M | — | ||
| Q1 24 | $680.0M | — |
| Q4 25 | $913.2M | $700.8M | ||
| Q3 25 | $904.9M | — | ||
| Q2 25 | $907.4M | — | ||
| Q1 25 | $966.7M | — | ||
| Q4 24 | $910.4M | — | ||
| Q3 24 | $991.1M | — | ||
| Q2 24 | $964.3M | — | ||
| Q1 24 | $869.8M | — |
| Q4 25 | — | 0.91× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $21.6M |
| Free Cash FlowOCF − Capex | $-61.9M | $21.4M |
| FCF MarginFCF / Revenue | -71.3% | 42.7% |
| Capex IntensityCapex / Revenue | 10.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $12.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $21.6M | ||
| Q3 25 | $-78.7M | $14.4M | ||
| Q2 25 | $-67.4M | $7.2M | ||
| Q1 25 | $-103.7M | $4.4M | ||
| Q4 24 | $-73.3M | — | ||
| Q3 24 | $-59.0M | $8.3M | ||
| Q2 24 | $-98.4M | — | ||
| Q1 24 | $-122.3M | $4.8M |
| Q4 25 | $-61.9M | $21.4M | ||
| Q3 25 | $-89.5M | $-7.3M | ||
| Q2 25 | $-74.9M | $-3.1M | ||
| Q1 25 | $-109.9M | $966.4K | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | $-2.4M | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | $218.9K |
| Q4 25 | -71.3% | 42.7% | ||
| Q3 25 | -132.7% | -22.2% | ||
| Q2 25 | -124.9% | -14.4% | ||
| Q1 25 | -222.8% | 9.2% | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | -12.3% | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | 2.4% |
| Q4 25 | 10.7% | 0.3% | ||
| Q3 25 | 16.1% | 66.1% | ||
| Q2 25 | 12.4% | 47.9% | ||
| Q1 25 | 12.6% | 32.5% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | 55.5% | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | 50.0% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LPA
Segment breakdown not available.
